secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001650664-25-000020
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas posts Q4 net loss $45.4M ($0.55/sh); ends reni-cel, cuts 65% staff
-------------------------------------------------------------------------

- Q4 2024 net loss $45.4M vs $18.9M in Q4 2023; full-year net loss $237.1M vs $153.2M.
- Cash $269.9M; operational runway into Q2 2027 includes $45-55M in restructuring costs.
- Ended reni-cel development due to failed partnership search; workforce reduced ~65%.
- On track to declare in vivo HSC and liver development candidates via gene upregulation mid-2025.
- No future quarterly earnings conference calls.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000020/0001650664-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000020/edit-20250305.htm
  HTML page:      https://secwatch.observer/filing/0001650664-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer